2013
Genetic Differences in Native Americans and Tacrolimus Dosing After Kidney Transplantation
Chakkera HA, Chang Y, Bodner JK, Behmen S, Heilman RL, Reddy KS, Mulligan DC, Moss AA, Khamash H, Katariya N, Hewitt WR, Pitta TL, Frassetto LA. Genetic Differences in Native Americans and Tacrolimus Dosing After Kidney Transplantation. Transplantation Proceedings 2013, 45: 137-141. PMID: 23375287, DOI: 10.1016/j.transproceed.2012.10.023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1Cohort StudiesFemaleGenetic VariationHumansImmunosuppressive AgentsIndians, North AmericanKidney Failure, ChronicKidney TransplantationMaleMiddle AgedPharmacogeneticsPolymorphism, Single NucleotideTacrolimusTime FactorsConceptsKidney transplant recipientsTrough levelsTacrolimus dosingTransplant recipientsSingle nucleotide polymorphismsDaily tacrolimus doseLower tacrolimus dosesTacrolimus pharmacokinetic parametersTacrolimus trough levelsCaucasian kidney transplant recipientsStable dosesTacrolimus doseKidney transplantationTacrolimus dosesTacrolimus pharmacokineticsMonths posttransplantationOral clearanceTacrolimus clearanceDrug eliminationPharmacokinetic parametersVariant single nucleotide polymorphismsTacrolimusDrug metabolismPharmacokinetic studyLow dosage
2011
A randomized, multicenter study comparing steroid‐free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C
Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Pomfret EA, Vargas HE, Brown R, Eckhoff D, Pruett TL, Roberts J, Mulligan DC, Charlton MR, Heffron TG, Ham JM, Douglas DD, Sher L, Baliga PK, Kinkhabwala M, Koneru B, Abecassis M, Millis M, Jennings LW, Fasola CG. A randomized, multicenter study comparing steroid‐free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transplantation 2011, 17: 1394-1403. PMID: 21850690, DOI: 10.1002/lt.22417.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAntibodies, Monoclonal, HumanizedAntiviral AgentsBiopsyChi-Square DistributionDaclizumabDrug Therapy, CombinationFemaleGraft RejectionHepacivirusHepatitis C, ChronicHumansImmunoglobulin GImmunosuppressive AgentsKaplan-Meier EstimateLiver FailureLiver TransplantationMaleMiddle AgedMycophenolic AcidProportional Hazards ModelsProspective StudiesRecurrenceRisk AssessmentRisk FactorsRNA, ViralSurvival RateTacrolimusTime FactorsTreatment OutcomeUnited StatesConceptsAcute cellular rejectionSteroid-free immunosuppressionLiver transplant recipientsHCV recurrenceMycophenolate mofetilTransplant recipientsHCV RNA-positive subjectsHepatitis C virus infectionSevere HCV recurrenceSteroid-free groupC virus infectionChronic hepatitis CGraft survival ratesProportion of patientsLiver biopsy samplesCellular rejectionChronic HCVStandard immunosuppressionSteroid sparingHepatitis CLess diabetesMulticenter trialMulticenter studyPatient survivalArm 1
2007
Laparoscopic incisional hernia repair after liver transplantation
Mekeel K, Mulligan D, Reddy KS, Moss A, Harold K. Laparoscopic incisional hernia repair after liver transplantation. Liver Transplantation 2007, 13: 1576-1581. PMID: 17969189, DOI: 10.1002/lt.21290.Peer-Reviewed Original ResearchConceptsLaparoscopic incisional hernia repairIncisional hernia repairLAP groupLiver transplantationHernia repairOP groupMore patientsLaparoscopic ventral hernia repairTime of transplantationLength of stayVentral hernia repairNontransplant patientsPrimary immunosuppressionWound complicationsRecurrent ascitesLaparoscopic approachMesh removalOpen repairRetrospective reviewDecreased incidenceMesh infectionIncisional herniaLower riskPatientsTransplantation
2005
Steroid Avoidance Immunosuppression in Low-Risk Kidney Transplant Recipients
Heilman R, Mazur M, Reddy K, Moss A, Post D, Mulligan D. Steroid Avoidance Immunosuppression in Low-Risk Kidney Transplant Recipients. Transplantation Proceedings 2005, 37: 1785-1788. PMID: 15919466, DOI: 10.1016/j.transproceed.2005.02.106.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsLow-risk kidney transplant recipientsChronic allograft nephropathyPostoperative day 3Steroid avoidanceTransplant recipientsLow-immunologic risk kidney transplant recipientsDay 3Anti-thymocyte globulin inductionRabbit anti-thymocyte globulinRisk kidney transplant recipientsIncidence of PTDMPositive flow crossmatchSteroid avoidance immunosuppressionTrough tacrolimus levelsAnti-thymocyte globulinGraft survival ratesSerum creatinine levelsShort-term safetyRecent clinical trialsDay of transplantationActuarial patientAcute rejectionAllograft nephropathyGlobulin induction
2003
Effects of tacrolimus on ischemia‐reperfusion injury
St. Peter SD, Moss AA, Mulligan DC. Effects of tacrolimus on ischemia‐reperfusion injury. Liver Transplantation 2003, 9: 105-116. PMID: 12548502, DOI: 10.1053/jlts.2003.50020.Peer-Reviewed Original ResearchConceptsEffects of tacrolimusIschemia-reperfusion injuryCellular mechanismsCalcium-activated pathwaysInteractions of tacrolimusFree radical metabolismCornerstone agentEfficacious immunosuppressionInflammatory cascadeOrgan transplantationTacrolimusCytoprotective effectsTissue recoveryClinical literatureDiverse actionsRadical metabolismImmunosuppressionInjuryMitochondrial stabilityStress response proteinsReperfusionIschemiaTransplantationTranscription factorsMicrocirculationTacrolimus as a liver flush solution to ameliorate the effects of ischemia/reperfusion injury following liver transplantation
St. Peter SD, Post DJ, Rodriguez‐Davalos M, Douglas DD, Moss AA, Mulligan DC. Tacrolimus as a liver flush solution to ameliorate the effects of ischemia/reperfusion injury following liver transplantation. Liver Transplantation 2003, 9: 144-149. PMID: 12548508, DOI: 10.1053/jlts.2003.50018.Peer-Reviewed Original ResearchConceptsIschemia/reperfusion injuryTacrolimus treatmentReperfusion injuryFlush solutionGroup 2Group 1Partial thromboplastin time valuesBaseline aspartate aminotransferaseEarly graft functionOrthotopic liver transplantProspective randomized fashionTotal ischemia timeSerum laboratory valuesSuperior early graft functionGraft functionLiver transplantLiver transplantationHepatic allograftsHepatocellular injuryLiver injuryPlacebo treatmentLiver diseasePlasma-Lyte AHepatocellular damageIschemia time